The ECLIPSE trials: com- parative studies of clevidipine to nitroglycerin, sodium nitroprus- side, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth Analg. 2008;107:1110 21. S11.5-20. Espinosa A, Ripolles-Melchor J, Casans-Frances R, et al. Perioperative use of clevidipine: a systematic review and meta- analysis. PLoS ONE. 2016;11:e0150625. S11.5-21. Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/ AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: execu- tive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:2215 45. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e105 S11.5-22. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458 73. S11.5-23. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413 46. S11.5-24. Wolfsthal SD. Is blood pressure control necessary before surgery? Med Clin North Am. 1993;77:349 63. S11.5-25. Goldman L, Caldera DL. Risks of general anesthesia and elec- tive operation in the hypertensive patient. Anesthesiology. 1979;50:285 92. S11.5-26. Towne JB, Bernhard VM. The relationship of postoperative hypertension to complications following carotid endarterectomy. Surgery. 1980;88:575 80. S11.5-27. Aronson S, Boisvert D, Lapp W. Isolated systolic hyper- tension is associated with adverse outcomes from coro- nary artery bypass grafting surgery. Anesth Analg. 2002;94: 1079 84. S11.5-28. Foex P, Meloche R, Prys-Roberts C. Studies of anaesthesia in rela- tion to hypertension. 3. Pulmonary gas exchange during spontane- ous ventilation. Br J Anaesth. 1971;43:644 61. S11.5-29. Gerber JG, Nies AS. Abrupt withdrawal of cardiovascular drugs. N Engl J Med. 1979;301:1234 5. S11.5-30. Rangno RE, Langlois S. Comparison of withdrawal phenom- ena after propranolol, metoprolol, and pindolol. Am Heart J. 1982;104:473 8. S11.5-31. Walker PR, Marshall AJ, Farr S, et al. Abrupt withdrawal of ateno- lol in patients with severe angina. Comparison with the effects of treatment. Br Heart J. 1985;53:276 82. 12. Strategies to Improve Hypertension Treatment and Control 12.1. Adherence Strategies for Treatment of Hypertension 12.1.1. Antihypertensive Medication Adherence Strategies S12.1.1-1. Claxton AJ, Cramer J, Pierce C. A systematic review of the asso- ciations between dose regimens and medication compliance. Clin Ther. 2001;23:1296 310. S12.1.1-2. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihyperten- sive pharmacotherapy: evidence from a meta-analysis. Clin Ther. 2002;24:302 16. S12.1.1-3. Schroeder K, Fahey T, Ebrahim S. How can we improve adher- ence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med. 2004;164:722 32. S12.1.1-4. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose com- binations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713 9. S12.1.1-5. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effec- tiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55:399 407. S12.1.1-6. Sherrill B, Halpern M, Khan S, et al. Single-pill vs free-equiva- lent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13:898 909. S12.1.1-7. Yang W, Chang J, Kahler KH, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010;26:2065 76. S12.1.1-8. Franklin SS, Thijs L, Hansen TW, et al. Significance of white- coat hypertension in older persons with isolated systolic hyper- tension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension. 2012;59: 564 71. S12.1.1-9. Holland N, Segraves D, Nnadi VO, et al. Identifying barriers to hypertension care: implications for quality improvement initia- tives. Dis Manag. 2008;11:71 77. S12.1.1-10. Berra E, Azizi M, Capron A, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68:297 306. S12.1.1-11. Gwadry-Sridhar FH, Manias E, Lal L, et al. Impact of interven- tions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. Value Health. 2013;16:863 71. S12.1.1-12. Petrilla AA, Benner JS, Battleman DS, et al. Evidence-based interventions to improve patient compliance with antihy- pertensive and lipid-lowering medications. Int J Clin Pract. 2005;59:1441 51. S12.1.1-13. Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304 14. S12.1.1-14. Krousel-Wood MA, Muntner P, Islam T, et al. Barriers to and determinants of medication adherence in hypertension manage- ment: perspective of the cohort study of medication adherence among older adults. Med Clin North Am. 2009;93:753 69. S12.1.1-15. Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;11:CD000011. S12.1.1-16. Viswanathan M, Golin CE, Jones CD, et al. Closing the quality gap: revisiting the state of the science (vol. 4: medication adher- ence interventions: comparative effectiveness). Evid RepTechnol Assess (Full Rep). 2012:1 685. S12.1.1-17. Kim MT, Hill MN, Bone LR, et al. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs. 2000;15:90 6. 12.1.2. Strategies to Promote Lifestyle Modification S12.1.2-1. Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardio- vascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation. 2010;122:406 41. S12.1.2-2. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(suppl 2): S76 99. 12.1.3. Improving Quality of Care for Resource- Constrained Populations S12.1.3-1. Havranek EP, Mujahid MS, Barr DA, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132:873 98. S12.1.3-2. Institute of Medicine (U.S.) Committee on Public Health Priorities to Reduce and Control Hypertension. A Population-Based Policy and Systems Change Approach to Prevent and Control Hypertension. 2010; National Academies Press: Washington, DC. S12.1.3-3. Margolius D, Bodenheimer T, Bennett H, et al. Health coaching to improve hypertension treatment in a low-income, minority popu- lation. Ann Fam Med. 2012;10:199 205. S12.1.3-4. Polgreen LA, Han J, Carter BL, et al. Cost-effectiveness of a physician-pharmacist collaboration intervention to improve blood pressure control. Hypertension. 2015;66:1145 51. S12.1.3-5. Brownstein JN, Chowdhury FM, Norris SL, et al. Effectiveness of community health workers in the care of people with hyperten- sion. Am J Prev Med. 2007;32:435 47. 12.2. Structured, Team-Based Care Interventions for Hypertension Control S12.2-1. Carter BL, Rogers M, Daly J, et al. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med. 2009;169:1748 55. S12.2-2. Clark CE, Smith LFP, Taylor RS, et al. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ. 2010;341:c3995. S12.2-3. Proia KK, ThotaAB, Njie GJ, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014;47:86 99. S12.2-4. Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pres- sure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3:e000718. S12.2-5. Shaw RJ, McDuffie JR, Hendrix CC, et al. Effects of nurse-man- aged protocols in the outpatient management of adults with chronic conditions: a systematic review and meta-analysis. Ann Intern Med. 2014;161:113 21. S12.2-6. Thomas KL, Shah BR, Elliot-Bynum S, et al. Check it, change it: a community-based, multifaceted intervention to improve blood pressure control. Circ Cardiovasc Qual Outcomes. 2014;7: 828 34. S12.2-7. Carter BL, Coffey CS, Ardery G, et al. Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pres- sure control. Circ Cardiovasc Qual Outcomes. 2015;8:235 43. S12.2-8. Himmelfarb CRD, Commodore-Mensah Y, Hill MN. Expanding the role of nurses to improve hypertension care and control glob- ally. Ann Glob Health. 2016;82:243 53. S12.2-9. The Guide to Community Preventive Services (The Community Guide). Cardiovascular Disease: Team-Based Care to Improve Blood Pressure Control. 2012. Available at: https://www.thecom- munityguide.org/findings/cardiovascular-disease-team-based-care- improve-blood-pressure-control. Accessed June 1, 2017. S12.2-10. Centers for Disease Control and Prevention. Task Force recom- mends team-based care for improving blood pressure control. Press Release. May 15, 2012. Available at: https://www.cdc.gov/media/ 2017. S12.2-11. Tsuyuki RT, Al Hamarneh YN, Jones CA, et al. The effectiveness of pharmacist interventions on cardiovascular risk: The Multicenter Randomized Controlled RxEACH Trial. J Am Coll Cardiol. 2016;67:2846 54. S12.2-12. Brownstein JN, Chowdhury FM, Norris SL, et al. Effectiveness of community health workers in the care of people with hypertension. Am J Prev Med. 2007;32:435 47. S12.2-13. Brush JE Jr, Handberg EM, Biga C, et al. 2015 ACC health policy statement on cardiovascular team-based care and the role of advanced practice providers. J Am Coll Cardiol. 2015;65: 2118 36. S12.2-14. Patient-Centered Primary Care Collaborative. The Patient- Centered Medical Home: Integrating Comprehensive Medication Management to Optimize Patient Outcomes: Resource Guide. 2010.Available at: https://www.pcpcc.org/sites/default/files/media/ medmanagement.pdf. Accessed June 15, 2017. S12.2-15. Dunn SP, Birtcher KK, Beavers CJ, et al. The role of the clinical pharmacist in the care of patients with cardiovascular disease. J Am Coll Cardiol. 2015;66:2129 39. 12.3. Health Information Technology Based Strategies to Promote Hypertension Control 12.3.1. EHR and Patient Registries S12.3.1-1. Rakotz MK, Ewigman BG, Sarav M, et al. A technology-based quality innovation to identify undiagnosed hypertension among active primary care patients. Ann Fam Med. 2014;12:352 8. S12.3.1-2. Borden WB, Maddox TM, Tang F, et al. Impact of the 2014 expert panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014;64:2196 203. S12.3.1-3. Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure con- trol associated with a large-scale hypertension program. JAMA. 2013;310:699 705. 12.3.2. Telehealth Interventions to Improve Hypertension Control S12.3.2-1. Omboni S, Gazzola T, Carabelli G, et al. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013;31:455 67; discussion 467 8. S12.3.2-2. Verberk WJ, Kessels AGH, Thien T. Telecare is a valuable tool for hypertension management, a systematic review and meta-analysis. Blood Press Monit. 2011;16:149 55. S12.3.2-3. Agarwal R, Bills JE, Hecht TJW, et al. Role of home blood pres- sure monitoring in overcoming therapeutic inertia and improv- ing hypertension control: a systematic review and meta-analysis. Hypertension. 2011;57:29 38. S12.3.2-4. Liu S, Dunford SD, Leung YW, et al. Reducing blood pressure with Internet-based interventions: a meta-analysis. Can J Cardiol. 2013;29:613 21. S12.3.2-5. Burke LE, Ma J, Azar KMJ, et al. Current science on consumer use of mobile health for cardiovascular disease prevention: a scien- tific statement from the American Heart Association. Circulation. 2015;132:1157 213. S12.3.2-6. Li JS, Barnett TA, Goodman E, et al. Approaches to the prevention and management of childhood obesity: the role of social networks and the use of social media and related electronic technolo- gies: a scientific statement from the American Heart Association. Circulation. 2013;127:260 7. S12.3.2-7. Omboni S, Ferrari R. The role of telemedicine in hypertension man- agement: focus on blood pressure telemonitoring. Curr Hypertens Rep. 2015;17:535. 12.4. Improving Quality of Care for Patients With Hypertension 12.4.1. Performance Measures S12.4.1-1. Svetkey LP, Pollak KI,Yancy WS Jr, et al. Hypertension improvement project: randomized trial of quality improvement for physicians and lifestyle modification for patients. Hypertension. 2009;54:1226 33. S12.4.1-2. de Lusignan S, Gallagher H, Jones S, et al. Audit-based educa- tion lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results. Kidney Int. 2013;84:609 20. S12.4.1-3. Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure con- trol associated with a large-scale hypertension program. JAMA. 2013;310:699 705. S12.4.1-4. Performance Management and Measurement. U.S. Department of Health and Human Services, Health Resources and Services Administration; 2011. Available at: https://www.hrsa.gov/sites/ measurement.pdf. Accessed October 30, 2017. S12.4.1-5. Bardach NS, Wang JJ, De Leon SF, et al. Effect of pay-for-per- formance incentives on quality of care in small practices with electronic health records: a randomized trial. JAMA. 2013;310:1051 9. S12.4.1-6. Navar-Boggan AM, Shah BR, Boggan JC, et al. Variability in per- formance measures for assessment of hypertension control. Am Heart J. 2013;165:823 7. Drozda J Jr, Messer JV, Spertus J, et al.ACCF/AHA/AMA-PCPI 2011 performance measures for adults with coronary artery disease and hyper- tension: a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. Circulation. 2011;124:248 70. S12.4.1-8. Powers BJ, Olsen MK, Smith VA, et al. Measuring blood pressure for decision making and quality reporting: where and how many measures? Ann Intern Med. 2011;154:781 8; W-289 90. S12.4.1-9. Bonow RO, Douglas PS, Buxton AE, et al. ACCF/AHA method- ology for the development of quality measures for cardiovascu- lar technology: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures. Circulation. 2011;124:1483 502. 12.4.2. Quality Improvement Strategies S12.4.2-1. Walsh JME, McDonald KM, Shojania KG, et al. Quality improve- ment strategies for hypertension management: a systematic review. Med Care. 2006;44:646 57. S12.4.2-2. Carter BL, Rogers M, Daly J, et al. The potency of team-based care interventions for hypertension: a meta-analysis. Arch Intern Med. 2009;169:1748 55. S12.4.2-3. Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2010:CD005182. S12.4.2-4. Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014;47:86 99. S12.4.2-5. Anchala R, Pinto MP, Shroufi A, et al. The role of Decision Support System (DSS) in prevention of cardiovascular disease: a systematic review and meta-analysis. PLoS ONE. 2012;7:e47064. S12.4.2-6. Thomas KL, Shah BR, Elliot-Bynum S, et al. Check it, change it: a community-based, multifaceted intervention to improve blood pressure control. Circ Cardiovasc Qual Outcomes. 2014;7:828 34. S12.4.2-7. Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure con- trol associated with a large-scale hypertension program. JAMA. 2013;310:699 705. Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e107 S12.4.2-8. Agarwal R, Bills JE, Hecht TJW, et al. Role of home blood pres- sure monitoring in overcoming therapeutic inertia and improv- ing hypertension control: a systematic review and meta-analysis. Hypertension. 2011;57:29 38. S12.4.2-9. Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63:878 85. S12.4.2-10. Walsh J, McDonald KM, Shojania KG, et al. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies (Vol. 3: Hypertension Care). Rockville, MD: Agency for Healthcare Research and Quality (U.S.); 2005. S12.4.2-11. Center for Medicare and Medicaid Services. Million Hearts: Cardiovascular Disease Risk Reduction Model. 2016. Available at: https://innovation.cms.gov/initiatives/Million-Hearts-CVDRRM/. Accessed October 30, 2017. 12.5. Financial Incentives S12.5-1. Hysong SJ, Simpson K, Pietz K, et al. Financial incentives and physician commitment to guideline-recommended hypertension management. Am J Manag Care. 2012;18:e378 91. S12.5-2. Petersen LA, Simpson K, Pietz K, et al. Effects of individual phy- sician-level and practice-level financial incentives on hypertension care: a randomized trial. JAMA. 2013;310:1042 50. S12.5-3. Karunaratne K, Stevens P, Irving J, et al. The impact of pay for perfor- mance on the control of blood pressure in people with chronic kidney disease stage 3 5. Nephrol Dial Transplant. 2013;28:2107 16. S12.5-4. Maimaris W, Paty J, Perel P, et al. The influence of health systems on hypertension awareness, treatment, and control: a systematic literature review. PLoS Med. 2013;10:e1001490. S12.5-5. Center for Medicare and Medicaid Services. Million Hearts: Cardiovascular Disease Risk Reduction Model. 2016.Available at: https://innovation.cms.gov/initiatives/Million-Hearts-CVDRRM/. Accessed October 30, 2017. 13. The Plan of Care for Hypertension S13-1. Jaffe MG, Young JD. The Kaiser Permanente Northern California story: improving hypertension control from 44% to 90% in 13 years (2000 to 2013). J Clin Hypertens (Greenwich). 2016;18:260 1. S13-2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124:2458 73. S13-3. Fihn SD, Blankenship JC,Alexander KP, et al. 2014ACC/AHA/AATS/ PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2014;130:1749 67. S13-4. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354 471. S13-5. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240 327. S13-6. Standards of Medical Care in Diabetes 2016: Summary of Revisions. Diabetes Care. 2016;39(suppl 1):S4 5. 15. Evidence Gaps and Future Directions S15-1. Moser M, Brown CM, Rose CH, et al. Hypertension in pregnancy: is it time for a new approach to treatment? J Hypertens. 2012;30: 1092 100. Key Words: AHA Scientific Statements ambulatory care antihypertensive agents behavior modification blood pressure chronic kidney disease diabetes hypertension hypertension emergency lifestyle measures measurement nonpharmacologic treatment resistant hypertension risk reduction secondary hypertension systems of care treatment adherence treatment outcomes Appendix 1. Author Relationships With Industry and Other Entities (Relevant) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (October 2017) Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Salary Paul K. Whelton, Chair Tulane University School of Hygiene and Tropical Medicine Show Chwan Professor of Global Public Health None None None None None None None Robert M. Carey, Vice Chair University of Virginia School of Medicine Dean, Emeritus, and Professor of Medicine None None None Daiichi Sankyo Inc None None None Wilbert S. Aronow Westchester Medical Center and New York Medical College Professor of Medicine None None None None None None None Donald E. Casey, Jr Thomas Jefferson College of Population Health Adjunct Faculty; Alvarez & Marsal Ipo4health Principal and Founder None None None None None None None Karen J. Collins Collins Collaboration President None None None None None None None Cheryl Dennison Himmelfarb John Hopkins University Professor of Nursing and Medicine, Institute for Clinical and Translational Research None None None None None None None Sondra M. DePalma PinnacleHealth CardioVascular Institute Physician Assistant; American Academy of PAs Director, Regulatory and Professional Practice None None None None None None None Samuel Gidding Alfred I. Dupont Hospital for Children Chief, Division of Pediatric Cardiology, Nemours Cardiac Center None None None None None None None David C. Goff, Jr* Colorado School of Public Health Professor and Dean, Department of Epidemiology None None None None None None None Kenneth A. Jamerson University of Michigan Health System Professor of Internal Medicine and Frederick G.L. Huetwell Collegiate Professor of Cardiovascular Medicine None None None None None None None Daniel W. Jones University of Mississippi Medical Center Professor of Medicine and Physiology; Metabolic Diseases and Nutrition University Sanderson Chair in Obesity Mississippi Center for Obesity Research Director, Clinical and Population Science None None None None None None None Eric J. MacLaughlin Texas Tech University Health Sciences Center Professor and Chair, Department of Pharmacy Practice, School of Pharmacy None None None None None None None Paul Muntner University of Alabama at Birmingham Professor, Department of Epidemiology None None None None None None None Bruce Ovbiagele Medical University of South Carolina Pihl Professor and Chairman of Neurology None Boehringer Ingelheim Korea Ltd None None None None None Sidney C. Smith, Jr University of North Carolina at Chapel Hill Professor of Medicine; Center for Cardiovascular Science and Medicine Director None None None None None None None Crystal C. Spencer Spencer Law, PA Attorney at Law None None None None None None None (Continued) Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e109 Randall S. Stafford Stanford Prevention Research Center Professor of Medicine; Program on Prevention Outcomes Director None None None None None None None Sandra J. Taler Mayo Clinic Professor of Medicine, College of Medicine None None None None None None None Randal J. Thomas Mayo Clinic Medical Director, Cardiac Rehabilitation Program None None None None None None None Kim A. Williams, Sr Rush University Medical Center James B. Herrick Professor; Division of Cardiology Chief None None None None None None None Jeff D. Williamson Wake Forest Baptist Medical Center Professor of Internal Medicine; Section on Gerontology and Geriatric Medicine Chief None None None None None None None Jackson T. Wright, Jr Case Western Reserve University Professor of Medicine; William T. Dahms MD Clinical Research Unit Program Director; University Hospitals Case Medical Center Director, Clinical Hypertension Program None Amgen None None None None None This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $5000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person s household, has a reasonable potential for financial, professional or other personal gain or loss as a result of the issues/content addressed in the document. We gratefully acknowledge the contributions of Dr. Lawrence Appel, who served as a member of the Writing Committee from November 2014 to September 2015. *Dr. David C. Goff resigned from the writing committee in December 2016 because of a change in employment before the recommendations were balloted. The writing committee thanks him for his contributions, which were extremely beneficial to the development of the draft. Significant relationship. AAPA indicates American Academy of Physician Assistants; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; AGS, American Geriatrics Society; AHA, American Heart Association; APhA, American Pharmacists Association; ASH, American Society of Hypertension; ASPC, American Society for Preventive Cardiology; ABC, Association of Black Cardiologists; NMA, National Medical Association; and PCNA, Preventive Cardiovascular Nurses Association. Appendix 1. Continued Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Salary Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Salary Kim K. Birtcher Official Reviewer TFPG Lead Reviewer University of Houston College of Pharmacy Clinical Professor, Department of Pharmacy Practice and Translational Research Jones & Bartlett Learning None None None Accreditation Council for Clinical Lipidology None Walgreens* Roger Blumenthal Official Reviewer Prevention Subcommittee Johns Hopkins Hospital Kenneth Jay Pollin Professor of Cardiology; Ciccarone Center for the Prevention of Heart Disease Director None None None None None None None Anna Dominiczak Official Reviewer AHA University of Glasgow Regius Professor of Medicine; Vice-Principal and Head of College of Medical, Veterinary and Life Sciences None None None None None None None Carlos M. Ferrario Official Reviewer AHA Wake Forest School of Medicine Professor, of Physiology and Pharmacology; Hypertension and Vascular Disease Center Director None None None None None None None Eugene Yang Official Reviewer ACC-BOG University of Washington School of Medicine Associate Clinical Professor of Medicine; UW Medicine Eastside Specialty Center Medical Director RubiconMD* Regeneron* None None Amgen Inc.* Gilead Sciences, Inc. (DSMB)* None Third party, None Robert Jay Amrien Organizational Reviewer AAPA Massachusetts General Hospital Clinical Physician Assistant, Chelsea Health Center; Bryant University Physician Assistant Program None None None None None Defendant, aortic dissection, None Greg Holzman Organizational Reviewer ACPM Montana Department of Public Health and Human Services State Medical Officer None None None None American Academy of Family Medicine American College of Preventive Medicine None None Martha Gulati Organizational Reviewer ASPC University of Arizona College of Medicine Professor of Medicine; Chief, Division of Cardiology; University Medicine Cardiovascular Institute in Phoenix Physician Executive Director, Banner None None None None REATA (spouse)* None None Wallace Johnson Organizational Reviewer NMA University of Maryland Medical Center Assistant Professor of Medicine None None None Amgen None None None Nancy Houston Miller Organizational Reviewer PCNA The Lifecare Company Associate Director Moving Analytics* None None None None None None (Continued) Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e111 Aldo J. Peixoto Organizational Reviewer ASH Yale University School of Medicine Professor of Medicine (Nephrology); Associate Chair for Ambulatory Services Operations and Quality, Department of Internal Medicine; Clinical Chief, Section of Nephrology Lundbeck Inc. None None Bayer Healthcare Pharmaceuticals Bayer Healthcare Pharmaceuticals None None Carlos Rodriguez Organizational Reviewer ABC Wake Forest University Professor, Epidemiology and Prevention Amgen Inc. None None None None None None Joseph Saseen Organizational Reviewer APhA University of Colorado Anschutz Medical Campus Vice-Chair, Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences None None None None National Lipid Association Defendant, statin use, None Mark Supiano Organizational Reviewer AGS University of Utah School of Medicine D. Keith Barnes, MD, and Dottie Barnes Presidential Endowed Chair in Medicine; Chief, Division of Geriatrics; VA Salt Lake City Geriatric Research Director, Education, and Clinical Center; University of Utah Center on Aging Executive Director None None None None American Geriatrics Society Division Chief McGraw-Hill Medical None None Sana M. Al-Khatib Content Reviewer ACC/AHA Task Force on Clinical Practice Guidelines Duke Clinical Research Institute Professor of Medicine None None None AHRQ* FDA* PCORI* VA Health System (DSMB) Elsevier* NIH, NHLBI Third party, implantable cardioverter defibrillators, None George Bakris Content Reviewer University of Chicago Medicine Professor of Medicine; Director, Hypertensive Diseases Unit None None None AbbVie, Inc. Janssen, Bayer, Relypsa None None None Jan Basile Content Reviewer Medical University of South Carolina Professor of Medicine, Seinsheimer Cardiovascular Health Program; Ralph H Johnson VA Medical Center Internist None Amgen Inc. Arbor Janssen Pharmaceuticals, Inc None Eli Lilly and Company NHLBI None None None Joshua A. Beckman Content Reviewer ACC/AHA Task Force on Clinical Practice Guidelines Vanderbilt University Medical Center: Director, Cardiovascular Fellowship Program, AstraZeneca* Merck* SANOFI* None EMX JanaCare Bristol Myers Squibb* Vascular Interventional Advances* None 2015 Defendant; Venous thromboembolism* John Bisognano Content Reviewer University of Rochester Medical Center Cardiologist CVRx None None CVRx* NIH* None None None Biykem Bozkurt Content Reviewer ACC/AHA Task Force on Clinical Practice Guidelines Baylor College of Medicine Medical Care Line Executive, Cardiology Chief, Gordon Cain Chair, Professor of Medicine, Debakey None None None Novartis Corporation None None None (Continued) Appendix 2. Continued Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Salary David Calhoun Content Reviewer University of Alabama, Birmingham School of Medicine Professor, Department of Cardiovascular Disease Novartis Valencia Technologies* None None MEDTRONIC* ReCor Medical* None None None Joaquin E. Cigarroa Content Reviewer ACC/AHA Task Force on Clinical Practice Guidelines Oregon Health and Science University Clinical Professor of Medicine None None None NIH ACC/AHA Taskforce on Clinical Practice Guidelines AHA, Board of Directors, Western Affiliate American Stroke Association, Cryptogenic Stroke Initiative Advisory Committee Catheterization and Cardiovascular Intervention SCAI Quality Interventional Council Defendant, Defendant, sudden death/ None William Cushman Content Reviewer Memphis VA Medical Center Chief, Preventive Medicine Section; University of Tennessee College of Medicine Professor, Medicine, Preventive Medicine, and Physiology None None None Lilly Novartis Corporation Takeda None None Anita Deswal Content Reviewer ACC/AHA Task Force on Clinical Practice Guidelines Baylor College of Medicine Associate Professor of Medicine None None None NIH* Aurora Health Care Inc. American Heart Association AHA Committee on Heart Failure and Transplantation Chair Heart Failure Society of America None None Dave Dixon Content Reviewer Cardiovascular Team Virginia Commonwealth University School of Pharmacy Associate Professor None None None None None None None Ross Feldman Content Reviewer Winnipeg Regional Health Authority Medical Director, Cardiac Sciences Program; University of Manitoba Professor of Medicine GSK* Servier* Valeant Pharmaceuticals International* None None None None None None Keith Ferdinand Content Reviewer Tulane University School of Medicine Professor of Clinical Medicine Amgen Inc.* Boehringer Ingelheim* Eli Lilly* Sanofi-Aventis* Novartis Quantum Genomics Sanofi-Aventis* None None None Novartis None None Stephan Fihn Content Reviewer University of Washington Professor of Medicine, Heath Services; Division Head, General Internal Medicine; Director, Office of Analytics and Business Intelligence for the Veterans Health Administration; VA Puget Sound Health Care System General Internist None None None None University of Washington None None (Continued) Appendix 2. Continued Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Salary Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e113 Lawrence Fine Content Reviewer National Heart, Lung and Blood Institute Chief, Clinical Applications and Prevention Branch, Division of Prevention and Population Sciences None None None None NIH* None None John Flack Content Reviewer Southern Illinois University School of Medicine Chair and Professor Department of Internal Medicine; Chief, Hypertension Specialty Services Regeneron* NuSirt None None Bayer Healthcare Pharmaceuticals GSK American Journal of Hypertension* CardioRenal Medicine International Journal of Hypertension Southern Illinois University Department of Medicine* None None Joseph Flynn Content Reviewer Seattle Children's Hospital Chief of the Division of Nephrology; University of Washington School of Medicine Professor of Pediatrics Ultragenyx, Inc. (DSMB) None None None UpToDate, Springer* None None Federico Gentile Content Reviewer ACC/AHA Task Force on Clinical Practice Guidelines Centro Cardiologico None None None None None None None Joel Handler Content Reviewer Kaiser Permanente Physician; National Kaiser Permanente Hypertension Clinical Leader None None None None None None None Hani Jneid Content Reviewer ACC/AHA Task Force on Clinical Data Standards Baylor College of Medicine Associate Professor of Medicine, MEDVAMC None None None None None None None Jos A. Joglar Content Reviewer ACC/AHA Task Force on Clinical Practice Guidelines UT Southwestern Medical Center Professor of Internal Medicine; Cardiovascular Clinical Research Center Director None None None None None None None Amit Khera Content Reviewer University of Texas Southwestern Medical Center Assistant Professor of Medicine None None None None None None None Glenn N. Levine Content Reviewer ACC/AHA Task Force on Clinical Practice Guidelines Baylor College of Medicine Professor of Medicine; Director, Cardiac Care Unit None None None None None Defendant, catheterization laboratory procedure, Defendant, interpretation of ECG of a Defendant, interpretation of angiogram (non-ACS), Defendant, out-of-hospital None (Continued) Appendix 2. Continued Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Salary Giuseppe Mancia Content Reviewer University of Milan- Bicocca Professor of Medicine; Chairman, Department of Clinical Medicine, Prevention and Applied Biotechnologies Boehringer Ingelheim* CVRx Ferrer MEDTRONIC Menarini International* Recordati Servier International* Actavis None None None Novartis* None None Andrew Miller Content Reviewer Geriatric Cardiology Section Cardiovascular Associates Cardiologist None None None Novartis Corporation Pfizer Inc Bristol-Myers Squibb Company Janssen Pharmaceuticals, Inc. NIH None None Pamela Morris Content Reviewer Prevention Council, Chair Seinsheimer Cardiovascular Health Program Director;Women's Heart CareMedical University of South Carolina Co-Director Amgen Inc. AstraZeneca Sanofi Regeneron None None Amgen Inc. None None None Martin Myers Content Reviewer Sunnybrook Health Sciences Centre Affiliate Scientist; University of Toronto Professor, Cardiology Ideal Life Inc* None None None None None None Rick Nishimura Content Reviewer Mayo Clinic College of Medicine Judd and Mary Morris Leighton Professor of Medicine;Mayo Clinic Division of Cardiovascular Diseases None None None None None None None Patrick T. O Gara Content Reviewer ACC/AHA Task Force on Clinical Practice Guidelines Harvard Medical School Professor of Medicine; Brigham and Women's Hospital Director, Strategic Planning, Cardiovascular Division None None None None MEDTRONIC NIH* None None Suzanne Oparil Content Reviewer University of Alabama at Birmingham Distinguished Professor of Medicine; Professor of Cell, Developmental and Integrative Biology, Division of Cardiology Actelion Lundbeck Novo Nordisk, Inc. None None AstraZeneca (Duke University)* Bayer Healthcare Pharmaceuticals, Inc.* Novartis* NIH* NIH/NHLBI, Takeda WHF/ ESH/EPH None None Carl Pepine Content Reviewer CV Disease in Women Committee Shands Hospital at University of Florida Professor of Medicine, Chief of Cardiovascular Medicine None None None Capricor, Inc. NIH Cytori Therapeutics, Inc. Sanofi-Aventis InVentive Health Clinical. LLC None None None Mahboob Rahman Content Reviewer Case Western Reserve University School of Medicine Professor of Medicine None None None None None None None Vankata Ram Content Reviewer UT Southwestern Medical Center; Apollo Institute for Blood Pressure Clinics None None None None None None None Barbara Riegel Content Reviewer ACC/AHA Task Force on Clinical Practice Guidelines University of Pennsylvania School of Nursing- Professor None None None Co-Investigator- mentor Co-investigator NIH NIH grant PCORI Novartis Corp None None (Continued) Appendix 2. Continued Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Salary Whelton et al 2017 High Blood Pressure Clinical Practice Guideline e115 Edward Roccella Content Reviewer National Heart, Lung, and Blood Institute Coordinator, National High Blood Pressure Education Program Medical University of South Carolina None None None American Society of Hypertension Consortium for Southeast Hypertension Control Consortium Southeast Hypertension Control Inter American Society of Hypertension None None Ernesto Schiffrin Content Reviewer Jewish General Hospital Physician- in-Chief, Chief of the Department of Medicine and Director of the Cardiovascular Prevention Centre; McGill University Professor, Department of Medicine, Division of Experimental Medicine Novartis Servier Novartis None Servier* Canadian Institutes for Health Research* CME Medical Grand Rounds None None Raymond Townsend Content Reviewer University of Pennsylvania School of Medicine Professor of Medicine; Director, Hypertension Section, Department of Internal Medicine/ Renal; Institute for Translational Medicine and Therapeutics Member MEDTRONIC None None NIH* ASN UpToDate None None Michael Weber Content Reviewer SUNY Downstate College of Medicine Professor of Medicine Ablative Solutions* Allergan, Inc Astellas Pharma US* Boston Scientific* Eli Lilly and Company MEDTRONIC* Novartis Recor Menarini* Merck & Co., Inc.* None None None None None This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% of the voting stock or share of the business entity, or ownership of $5 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees. *Significant relationship. No financial benefit. AHRQ indicates Agency for Healthcare Research and Quality; AAPA, American Academy of Physician Assistants; ACC, American College of Cardiology; ACPM, American College of Preventive Medicine; AGS, American Geriatrics Society; AHA, American Heart Association; APhA, American Pharmacists Association; ASH, American Society of Hypertension; ASPC, American Society for Preventive Cardiology; ABC, Association of Black Cardiologists; BOG, Board of Governors; CME, continuing medical education; DSMB, Data and Safety Monitoring Board; FDA, US Food and Drug Administration; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health; NMA, National Medical Association; PCNA, Preventive Cardiovascular Nurses Association; PCORI, Patient-Centered Outcomes Research Institute; SCAI, Society for Cardiovascular Angiography and Interventions; SUNY, State University of New York; TFPG, Task Force on Practice Guidelines; and UT, University of Texas. Appendix 2. Continued Reviewer Representation Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Salary